NZ748173A - Macrocyclic mcl1 inhibitors for treating cancer - Google Patents
Macrocyclic mcl1 inhibitors for treating cancerInfo
- Publication number
- NZ748173A NZ748173A NZ748173A NZ74817317A NZ748173A NZ 748173 A NZ748173 A NZ 748173A NZ 748173 A NZ748173 A NZ 748173A NZ 74817317 A NZ74817317 A NZ 74817317A NZ 748173 A NZ748173 A NZ 748173A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- solid form
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia- 5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
Claims (15)
1. A compound which is 17-chloro-5,13,14,22-tetramethyloxa-2,9-dithia- 4,7 11,15 16,21 20,24 30,35 5,6,12,13,22-pentaazaheptacyclo[27.7.1.1 .0 .0 .0 .0 ]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaenecarboxylic acid (Formula I) or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, wherein the compound is Formula I.
3. The compound of claim 1, wherein the compound is a pharmaceutically acceptable salt of the compound of Formula I.
4. The compound of claim 1, wherein the compound of Formula I has the structure of (R )chloro-5,13,14,22-tetramethyloxa-2,9-dithia-5,6,12,13,22- 4,7 11,15 16,21 20,24 30,35 pentaazaheptacyclo[27.7.1.1 .0 .0 .0 .0 ]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaenecarboxylic acid (Formula II) or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4, wherein the compound is Formula II.
6. The compound of claim 4, wherein the compound is a pharmaceutically acceptable salt of Formula II.
7. The compound of claim 1, wherein the compound of Formula I has the structure of (S )chloro-5,13,14,22-tetramethyloxa-2,9-dithia-5,6,12,13,22- 4,7 11,15 16,21 20,24 30,35 pentaazaheptacyclo[27.7.1.1 .0 .0 .0 .0 ]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaenecarboxylic acid (Formula III) (III) or a pharmaceutically acceptable salt thereof.
8. The compound of claim 7, wherein the compound is Formula III.
9. The compound of claim 7, wherein the compound is a pharmaceutically acceptable salt of Formula III.
10. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-9, in crystalline form.
11. The compound of claim 4, wherein the compound is a solid form of Formula II.
12. The solid form of claim 11, wherein the solid form is Form A (R )chloro- 5,13,14,22-tetramethyloxa-2,9-dithia-5,6,12,13,22- 4,7 11,15 16,21 20,24 30,35 pentaazaheptacyclo[27.7.1.1 .0 .0 .0 .0 ]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaenecarboxylic acid monohydrate.
13. The solid form of claim 12, wherein the solid form has an XRPD pattern comprising at least one peak expressed as 2? (±0.2º) selected from about 7.0°, 8.4° and 12.5°.
14. The solid form of claim 12, wherein the solid form has an XRPD pattern comprising at least one peak expressed as 2? (±0.2º) selected from about 5.4°, 7.0°, 8.4°, 10.7°, 12.5°, 13.1°, 14.4°, 15.1°, 15.6°, 17.1° and 18.2°.
15. The solid form of claim 12, wherein the solid form has an XRPD pattern substantially similar to
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326156P | 2016-04-22 | 2016-04-22 | |
| PCT/EP2017/059511 WO2017182625A1 (en) | 2016-04-22 | 2017-04-21 | Macrocyclic mcl1 inhibitors for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ748173A true NZ748173A (en) | 2025-05-02 |
| NZ748173B2 NZ748173B2 (en) | 2025-08-05 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502227A1 (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| AU2015221439B2 (en) | Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same | |
| EP4541422A3 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| TN2019000170A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| MX2024000299A (en) | Anti-viral compounds. | |
| EP4365179A3 (en) | Novel rapamycin derivatives | |
| PH12018500360A1 (en) | Heteroaryl derivatives as parp inhibitors | |
| WO2017123884A8 (en) | Heterocyclic compounds as rsv inhibitors | |
| MX2022015207A (en) | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections. | |
| TN2016000090A1 (en) | Substituted quinolizine derivatives useful as hiv integrase inhibitors. | |
| MX2019004951A (en) | PROCESS FOR THE PREPARATION OF PIRAZOLO [1,5-A] PYRIMIDINES AND SALTS OF THESE. | |
| WO2014172188A3 (en) | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors | |
| WO2012030685A3 (en) | Indazole derivatives useful as erk inhibitors | |
| MY197116A (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
| WO2008142720A3 (en) | Quinazolin-oxime derivatives as hsp90 inhibitors | |
| MX2012009186A (en) | Substituted pyrrolidine-2-carboxamides. | |
| MX2016016538A (en) | Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors. | |
| WO2013177534A3 (en) | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | |
| MX2018008095A (en) | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors. | |
| UA89123C2 (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| MX2020011317A (en) | Tricyclic heterocycle compounds useful as hiv integrase inhibitors. | |
| WO2018209363A3 (en) | Propionic acid derivatives and methods of use thereof | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| WO2018201167A3 (en) | Propionic acid derivatives and methods of use thereof | |
| WO2018035346A8 (en) | Kinase inhibitor compounds, compositions, and methods of treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2027 BY ANAQUA SERVICES Effective date: 20260320 |